Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody–Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers
Thomas M. Cardillo(Immunomedics (United States)), David M. Goldenberg(Unknown), Roberto Arrojo(Immunomedics (United States)), Robert M. Sharkey(Immunomedics (United States)), Serengulam V. Govindan(Dana-Farber Cancer Institute), Donglin Liu(Boston University), Chien‐Hsing Chang(Immunomedics (United States)), Edmund A. Rossi(Immunomedics (United States)), Preeti Trisal(Immunomedics (United States))
Cited by 302
Related Papers
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846
Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
|Oncotarget|2015|464
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2017|407